- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adagene Inc (ADAG)
Track today's live Adagene (ADAG) share price, performance and key data on this page with our current NASDAQ:ADAG stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Adagene share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ADAG share price, head to our technical summary section, which provides analysis on Adagene share price buy/sell indicators using real-time data (or discuss the Adagene (ADAG) stock price today with other investors in the Adagene NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ADAG share price (ISIN: US0053291078) to enhance your trading decisions with our free investment tools and resources.
What Is the Adagene Inc Share Price Today?
The Adagene share price today is 3.310.
What Is the Stock Symbol for Adagene Inc
The stock symbol (or 'ticker') for Adagene Inc is "ADAG."
What Stock Exchange Does Adagene Inc Trade On?
Adagene Inc is listed and trades on the NASDAQ stock exchange.
Is Adagene Inc a Good Stock to Buy?
Determining whether Adagene (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ADAG share price (ISIN: US0053291078) to enhance your trading decisions with our free investment tools and resources.
What Is the Adagene Inc Share Price Today?
The Adagene share price today is 3.310.
What Is the Stock Symbol for Adagene Inc
The stock symbol (or 'ticker') for Adagene Inc is "ADAG."
What Stock Exchange Does Adagene Inc Trade On?
Adagene Inc is listed and trades on the NASDAQ stock exchange.
Is Adagene Inc a Good Stock to Buy?
Determining whether Adagene (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.200
3.552
52 wk Range
1.300
4.850
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2003.552
52 wk Range
1.3004.850
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADAG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
10.090
Upside
+204.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Form 13D/A Adagene For: 8 June- Investing.com
Form 13G ADAGENE INC. For: 7 May- Investing.com
Adagene DRC receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Adagene DRC receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.090
(+204.83% Upside)
Earnings
Latest Release
12/08/2026
EPS / Forecast
-0.20 / -0.19
Revenue / Forecast
1.6M / --
Compare ADAG to Peers and Sector
Metrics to compare | ADAG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −3.2x | −0.3x | |
PEG Ratio | −0.28 | −0.29 | 0.00 | |
Price/Book | 2.5x | 3.8x | 2.6x | |
Price / LTM Sales | 23.9x | 24.7x | 3.0x | |
Upside (Analyst Target) | 145.4% | 142.1% | 53.8% | |
Fair Value Upside | Unlock | 6.8% | 8.6% | Unlock |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Adagene (NASDAQ: ADAG) Share Price Today?
The Adagene stock price today is 3.310 USD.
What Stock Exchange Does Adagene (ADAG) Trade On?
Adagene is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Adagene?
The stock symbol (also called a 'ticker') for Adagene is "ADAG."
What Is the Current Adagene Market Capitalisation?
As of today, Adagene (NASDAQ: ADAG) market cap is 222.240M USD.
What Is Adagene's (ADAG) Earnings Per Share (TTM)?
The Adagene EPS is currently -0.395 (Trailing Twelve Months).
When Is the Next Adagene Earnings Date?
Adagene's next earnings report will be released on 02/12/2026.
Is ADAG a Buy or Sell From a Technical Analyst Perspective?
Based on today's Adagene moving averages and other technical indicators, the daily buy/sell signal for ADAG stock is Strong Sell.
How Many Times Has Adagene Stock Split?
Adagene has split 0 times. (See the ADAG stock split history page for full effective split date and price information.)
How Many Employees Does Adagene Have?
Adagene has 128 employees, based on their latest Companies House report.
What is the current trading status of Adagene (NASDAQ: ADAG)?
As of 11/09/2026, Adagene (ADAG) is trading at a share price of 3.310 USD, with a previous close of 3.310 USD. The stock has fluctuated within a day range of 3.200 USD to 3.552 USD, while its 52-week range spans from 1.300 USD to 4.850 USD.
What Is Adagene (ADAG) Price Target According to Analysts?
The average 12-month price target for Adagene is 10.090 USD, with a high estimate of 17.45 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +204.83% Upside potential.
What Is the ADAG Premarket Price?
ADAG's last pre-market stock price is 3.150 USD. The pre-market share volume is 390.000, and the stock has decreased by -0.160, or -4.830%.
What Is the ADAG After Hours Price?
ADAG's last after hours stock price is 3.250 USD, the stock has decreased by -0.060, or -1.810%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.